Clinical Trials on Alzheimer's Disease

European Alzheimer's Disease Consortium
Montpellier and Toulouse EADC Centers

October 29-30, 2009
Las Vegas
Lou Ruvo Center for Brain Health

http://www.ctad.fr
on Alzheimer’s Disease

Dear Colleague,

It is a great honor to include you as a participant in the second annual Clinical Trials on Alzheimer’s Disease [CTaD’09] conference which will take place in Las Vegas, October 29-30, 2009.

This year, CTaD’09 is jointly organized by the Montpellier and Toulouse European Alzheimer’s Disease Consortium (EADC) Centers, and the Cleveland Clinic Lou Ruvo Center for Brain Health. The objective of the meeting is to create a forum for discussion among key opinion leaders in therapy development for Alzheimer’s disease.

The topics of discussion will include preliminary or new results concerning drug discovery, clinical trials of new therapies in development, methodological issues relating to disease modifying treatments, outcome measurements, biomarkers validation and health economics.

We look forward to seeing you in Las Vegas!

Sincerely

Zaven KHACHATURIAN, Jacques TOUCHON, Bruno VELLAS
Co-Chairs CTaD’09 Las Vegas, Nevada

Scientific Committee
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Maria CARRILLO (Chicago)
Bruno DUBOIS (Paris)
Howard FELDMAN (Vancouver)
Giovanni B. FRISONI (Brescia)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GIACOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Zaven KHACHATURIAN (Las Vegas)
Virginia LEE (Philadelphia)
Jean-Marc ORGOGOZO (Bordeaux)
Ronald PETERSEN (Rochester)
Lon SCHNEIDER (Los Angeles)
Peter SNYDER (Providence)
Eric SIEMERS (Philadelphia)
Yaakov STERN (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. WEINER (San Francisco)
Bengt WINBLAD (Stockholm)

Organizing Committee
Zaven KHACHATURIAN (Las Vegas)
Jacques TOUCHON (Montpellier)
Bruno VELLAS (Toulouse)

Congress secretariat
ANT Congrès
154 avenue de Lodève - 34070 Montpellier - France
E-mail : ctad09@ant-congres.com - Tel : + 33 (0)4 67 10 92 23
CONTENTS

Program ............................................................ p. 2 - 7
  Thursday, October 29th ....................................... p. 2 - 4
  Friday, October 30th ........................................... p. 5 - 7
Posters .............................................................. p. 8 - 12
CME ................................................................... p. 13
General Information ......................................... p. 13

Thursday, October 29th

8:30 - 10:00 a.m | LECTURES: Pre Dementia Alzheimer’s Disease Clinical Trials
10:00 - 10:30 a.m | Coffee Break and poster session
10:30 - 12:00 p.m | LECTURES: Preventive Trials in Alzheimer’s Disease
12:00 - 1:00 p.m | Lunch Break
1:00 - 2:00 p.m  | ORAL COMMUNICATIONS
2:00 - 3:30 p.m  | The German Network on Alzheimer’s Trials
3:30 - 4:00 p.m  | Coffee Break and poster session
4:00 - 5:45 p.m  | ORAL COMMUNICATIONS
6:00 p.m        | Guided tour of Cleveland Clinic Lou Ruvo Center for Brain Health

Friday, October 30th

8:30 - 9:30 a.m  | LECTURES: Update on Disease - Modifying Trials
9:30 - 12:15 p.m | PANEL DISCUSSION
12:15 - 1:00 p.m | Lunch Break
1:00 - 2:30 p.m  | ORAL COMMUNICATIONS
2:30 - 3:30 p.m  | LECTURES: Symptomatic Trials / Disease - Modifying Trials
3:30 - 4:00 p.m  | Coffee Break and poster session
4:00 - 5:30 p.m  | ORAL COMMUNICATIONS

MAJOR SPONSORS

- Eisai
- elan
- IPSEN
- JANSSEN-CILAG
- NOVARTIS
- Pfizer
- Wyeth
Thursday, October 29th

LECTURES : PRE DEMENTIA ALZHEIMER’S DISEASE CLINICAL TRIALS

Chairmen : B. Dubois (Paris), L. Schneider (Los Angeles)

8:30 - 9:00 a.m  L1 Pre Dementia Alzheimer’s trials : Overview
P. AISEN, San Diego

9:00 - 9:30 a.m  L2 Place of biomarkers in Pre Dementia Alzheimer’s Trials
M. WEINER, San Francisco

9:30 - 10:00 a.m  L3 Target Population : MCI vs. Pre Dementia Alzheimer’s Disease (New Criteria)
R. PETERSEN, Rochester

10:00 - 10:30 a.m  Coffee Break and poster session

LECTURES : PREVENTIVE TRIALS IN ALZHEIMER’S DISEASE

Chairmen : M. Weiner (San Francisco), Z. Khachaturian (Las Vegas)

10:30 - 11:00 a.m  L4 The future for preventive trials
L. SCHNEIDER, Los Angeles

11:00 - 11:30 a.m  L5 Clinical decline in patients who converted to AD in the GUIDAGE study
J. TOUCHON (1), B. VELLAS (2), (1) Montpellier, (2) Toulouse

11:30 - 12:00 p.m  L6 Multidomain preventive trials : Methodological issues
M. SANO, Philadelphia

12:00 - 1:00 p.m  Lunch Break

ORAL COMMUNICATIONS - Chairman : L. Frölich (Mannheim)*

1:00 - 1:15 p.m  O1 NOVEL TRIAL DESIGN FOR PRIMARY PREVENTION TRIALS OF DISEASE-MODIFYING THERAPIES IN AD
D. Darby (1,4), A. Brodtmann (4), M. Woodward (3), P. Maruff (1,2)
(1) CogState Ltd, Melbourne, AUSTRALIA
(2) Centre for Neuroscience, University of Melbourne, Parkville, AUSTRALIA
(3) Heidelberg Repatriation Hospital, Austin Health, West Heidelberg, AUSTRALIA
(4) Florey Neurosciences Institute, Parkville, AUSTRALIA

1:15 - 1:30 p.m  O2 MEMORY CAPACITY TEST (MCT) TO DETECT PRE-SYMPTOMATIC MEMORY IMPAIRMENT AND ALZHEIMER’S DISEASE
H. Buschke, Albert Einstein College of Medicine, Bronx, NY USA

*TBC
Thursday, October 29th

1:30 - 1:45 p.m  O3 PREDICTION OF COGNITIVE DECLINE IN HEALTHY OLDER INDIVIDUALS USING TASK-ACTIVATED FMRI, HIPPOCAMPAL VOLUMES, AND APOE STATUS  
S.M. Rao, J.L. Woodard, K.A. Nielson, S. Durgerian, P. Antuono, R. Schiffer  
Cleveland Clinic, Medical College of Wisconsin, Marquette University, Rosalind Franklin University of Medicine and Science, & Wayne State University

1:45 - 2:00 p.m  O4 HYPERTENSION AS A TREATMENT TARGET FOR PREVENTION OF DEMENTIA: CONSIDERATIONS FOR TRIAL DESIGN BASED ON EXPERIENCE OF THE SCOPE AND PRoFESSION COGNITIVE SUBSTUDIES  
B.K. Saxby (1), K.A. Wesnes (2), G.A. Ford (3)  
(1) Cognitive Drug Research Ltd., Chicago, USA  
(2) Cognitive Drug Research Ltd., Goring-on-Thames, UK  
(3) Clinical Research Centre, Newcastle University, UK

2:00 - 3:30 p.m  THE GERMAN COMPETENCE NETWORK ON DEMENTIA – Initial results on Biomarkers and Clinical Trials

2:00 - 2:20 p.m  S1 Cohort Characteristics and CSF studies of the German Dementia Competence Network (DCN)  
L. FRÖLICH, Mannheim

2:20 - 2:40 p.m  S2 Multicenter 1H-MRS studies in Alzheimer’s Disease and MCI in the German Competence Network (DCN)  
F. JESSEN, Bonn

2:40 - 3:00 p.m  S3 Genetic studies in AD in the German Dementia Competence Network (DCN)  
W. MAIER, Bonn

3:00 - 3:20 p.m  S4 A multi-center clinical trial on the long-term efficacy of a combination of galantamine and memantine in Alzheimer’s disease  
O. PETERS, Berlin

3:30 - 4:00 p.m  Coffee Break and poster session

ORAL COMMUNICATIONS : Miscellaneous – Chairman : J. Touchon (Montpellier)

4:00 - 4:15 p.m  O5 PSYCHOMETRIC PROPERTIES AND CLINICAL SIGNIFICANCE OF THE DEPENDENCE SCALE AS AN OUTCOME IN ALZHEIMER’S DISEASE  
K. Wyrwich (1), L. Frank (1), C. Leibman (2), L. Mucha (3), T. McLaughlin (2)  
(1) United BioSource Corporation, Bethesda, MD, USA  
(2) Elan Pharmaceuticals, Inc., South San Francisco, CA, USA  
(3) Wyeth Research, Collegeville, PA, USA
**Clinical Trials on Alzheimer’s Disease**

**Thursday, October 29**

4:15 - 4:30 p.m  
**O6 IDENTIFICATION OF PATIENTS WITH ALZHEIMER’S DISEASE USING MOLECULAR SIGNATURES DERIVED FROM SPLICE VARIANT EXPRESSION PROFILES FROM PERIPHERAL BLOOD**  
(1) ExonHit Therapeutics S.A., 63-65, Bld Masséna, Paris, FRANCE  
(2) ExonHit Therapeutics Inc., 217 Perry Parkway, Gaithersburg, MD, USA  
(3) Gerontopole Toulouse University Hospital, Inserm U 558, FRANCE

4:30 - 4:45 p.m  
**O7 IMPAIRMENT OF COGNITION: A HEALTH CARE SERVICES CHALLENGE FOR THE TWENTY-FIRST CENTURY**  
*M.D. Schiffer, L. Tara, M.H.A. Estabrooks, A. Loughrin, C. Talerico, B. Randolph*  
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, USA

4:45 - 5:00 p.m  
**O8 EVOLUTION OF CLINICAL TRIALS IN DEMENTIA FOR APPROVED AND NOVEL COMPOUNDS: COMPARING 2009 TO 2007**  
*T. Alaama (3), M. Smith (2,4,5,6), S. Woolmore-Goodwin (1,3,4), J. Wells (1,2,3,4,5,6), T. Purcell (6), M. Borrie (1,2,3,4,5,6)*  
(1) St. Joseph’s Health Care London, Ontario, CANADA  
(2) Lawson Health Research Institute, Ontario, CANADA  
(3) University of Western Ontario, Ontario, CANADA  
(4) Aging Rehabilitation and Geriatric Care, Ontario, CANADA  
(5) Geriatric Clinical Trials Group, Ontario, CANADA  
(6) Consortium of Canadian Centres for Clinical Cognitive Research, Ontario, CANADA

5:00 - 5:15 p.m  
**O9 NIA FUNDED ALZHEIMER CENTERS ARE MORE EFFICIENT THAN COMMERCIAL CLINICAL RECRUITMENT SITES FOR PERFORMING SECONDARY PREVENTION TRIALS OF DEMENTIA**  
*S.D. Edland (1), J.A. Emond (1), P.S. Aisen (1), R.C. Petersen (2)*  
(1) University of California San Diego, La Jolla, CA, USA  
(2) Mayo Clinic, Rochester, MN, USA

5:15 - 5:30 p.m  
**O10 ROLE OF CAREGIVER IN SUBJECT’S COMPLIANCE WITH TREATMENT**  
*V. Messick, P. Aisen, R. Raman, J. Edmond, R. Thomas*  
Alzheimer’s Disease Cooperative Study / University of California San Diego 9500 Gilman Drive 0949 La Jolla, CA, USA

5:30 - 5:45 p.m  
**O11 A BI-DIRECTIONAL EFFECT OF NAPROXEN ON THE PATHOGENESIS OF AD: CLINICAL AND BIOLOGICAL EVIDENCE FROM A RANDOMIZED PRIMARY PREVENTION TRIAL**  
*J. Breitner*  
Seattle, USA

6:00 p.m  
Guided tour of Cleveland Clinic Lou Ruvo Center for Brain Health
Friday, October 30th

LECTURES: UPDATE ON DISEASE - MODIFYING TRIALS
Chairmen: B. Vellas (Toulouse), R. Katz (Rockville)

8:30 - 9:00 a.m  L7 Gamma secretase inhibitors
H. Feldman, Vancouver

9:00 - 9:30 a.m  L8 Passive immunotherapy
M. Grundman, San Diego

PANEL DISCUSSION
«Approaches for identification of at-risk, but asymptomatic, subjects for longitudinal or prevention studies»


Topics of discussion:
1. APOE as predictive markers for age of onset
2. Longitudinal study of adult children of people with AD
3. PET study. Adult children of people with AD
4. ADNI Biomarker experience
5. Early neuropsychological markers
6. Study of risk for AD in older adults
7. Other related issues

10:30 - 11:00 a.m  Coffee Break

12:15 - 1:00 p.m  Lunch Break

ORAL COMMUNICATIONS - Chairman: R. Doody (Houston)

1:00 - 1:15 p.m  O12 A Novel T Cell Independent Liposomal Vaccine for the Treatment of Patients with Alzheimer’s Disease
(1) AC Immune SA, PSE Building B, EPFL, 1015 Lausanne, SWITZERLAND
(2) JSW Life Sciences, Graz, Parkring 12, 8074 Grambach, AUSTRIA
(3) reMYND, Gaston Geenslaan 1, 3001 Leuven-Heverlee, BELGIUM
(4) Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, 8091 Zurich, SWITZERLAND

1:15 - 1:30 p.m  O13 ANALYSIS OF LONGITUDINAL TEST SCORE DATA FROM ALZHEIMER’S DISEASE TRIALS USING REPEATED MEASURES: COMPARING CATEGORICAL VERSUS CONTINUOUS TIME MODELS VIA SIMULATION
G. Crans, K.M. Gregg
Elan Pharmaceuticals, South San Francisco, USA
Friday, October 30th

1:30 - 1:45 p.m
O14 A DIRECT SAMPLE SIZE COMPARISON BETWEEN MRI TEMPORAL HORN VOLUMES, CSF AB1-42 AND COGNITIVE DECLINE TO DETECT ALZHEIMER DISEASE PROGRESSION IN ADNI PARTICIPANTS
S.M. Nestor (1,2,4), M. Borrie (3,4), M. Smith (4), J. L. Wells (3,4), R. Bartha (1,2)
(1) Centre for functional and metabolic mapping, Robarts Research Institute, London, CANADA
(2) The departments of medical biophysics
(3) Medicine, University of Western Ontario, London, CANADA
(4) Division of aging, rehabilitation, and geriatric care, Lawson Health Research Institute, London, CANADA

1:45 - 2:00 p.m
O15 TESTING A LEPTIN PRODUCT AS A NOVEL THERAPY FOR ALZHEIMER’S DISEASE
J.W. Ashford (1), M.A. Smith (2), G. Casadesus (2), S.J. Greco (3), J.M. Johnston (3), N. Tezapsidis (3)
(1) Stanford /va aging clinical research center, vapa-hcs, palo alto, CA USA
(2) Case western reserve university, cleveland, OH, USA
(3) Neurotez, inc., bridgewater, NJ, USA

2:00 - 2:15 p.m
O16 REGIONAL CEREBRAL GLUCOSE METABOLISM PREDICTS DECLINE IN MCI SUBJECTS AND PROVIDES A SENSITIVE BIOMARKER OF DISEASE PROGRESSION
D. Matthews (1), R. Andrews (1), K. Rickert (1), L. Mosconi (2), W. Tsui (2), Y. Li, M. DeLeon (2), and the Alzheimer’s Disease Neuroimaging Initiative
(1) Abiant, Inc., Deerfield, Illinois, USA
(2) New York University Center for Brain Health, New York, USA

LECTURES: SYMPTOMATIC TRIALS / DISEASE-MODIFYING TRIALS
Chairmen: P. Aisen (San Diego), C. Sampaio (Lisbonne)

2:30 - 2:50 p.m
L9 New Insights into Dimebon (latrepirdine) Pharmacology in AD and HD Patients
A. PROTTER, San Francisco

2:50 - 3:10 p.m
L10 Update on Dimebon
R. DOODY, Houston

3:10 - 3:30 p.m
L11 Safety and exploratory efficacy of EHT 0202 in mild to moderate AD patients: a 3-month, randomized, double-blind, placebo-controlled, phase II A study
B. VELLAS, P.J. OUSSET, O. SOL, L. DESIRE, M. PANDO, Toulouse

3:30 - 4:00 p.m
Coffee Break and poster session
**Friday, October 30th**

**ORAL COMMUNICATIONS** - Chairmen: M. Sano (Philadelphia)*, M. Carillo (Chicago)

4:00 - 4:15 p.m  
**O17 CITALOPRAM FOR AGITATION IN ALZHEIMER’S DISEASE (CitAD)**  
I. Zahinoor, University of Toronto, Queen St W, Toronto Ontario, CANADA

4:15 - 4:30 p.m  
**O18 REDUCING MEASUREMENT ERROR USING THE MEMORY PERFORMANCE INDEX**  
W.R. Shankle, Medical Care Corporation, Irvine, CA, USA

4:30 - 4:45 p.m  
**O19 HTA-SADD (STUDY OF ANTIDEPRESSANTS FOR DEPRESSION IN DEMENTIA) – PRELIMINARY DATA FROM A MULTICENTRE PRAGMATIC RCT**  
S. Banerjee on behalf of the HTA-SADD Trial team  
Professor of Mental Health and Ageing, PO26, The Institute of Psychiatry, King’s College London, London, UK

4:45 - 5:00 p.m  
**O20 VENTRICULAR ATROPHY AND ITS CLINICAL CORRELATES IN THE IMAGING COHORT FROM THE ADCS MCI DONEPEZIL/VITAMIN E STUDY**  
(1) University of California Los Angeles, Los Angeles, CA, USA  
(2) Northwestern University, Chicago, IL, USA  
(3) Mayo Clinic, Rochester, MN, USA  
(4) University of California San Diego, San Diego, CA, USA

5:00 - 5:15 p.m  
**O21 EFFICACY AND TOLERABILITY OF ONE YEAR MEMANTINE (20 MG) TREATMENT IN BEHAVIORAL VARIANT OF FRONTOTEMPORAL DEMENTIA (BV-FTD): DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED TRIAL**  
M. Vercelletto (1), C. Boutoleau-Bretonnière (1), C. Volteau (2), M. Puel (3), S. Auricacme (4), M. Sarazin (5), B. Michel (6), P. Couratier (7), C. Thomas Anterion (8), A. Gabelle (9), P. Verpillat (10), É. Cerato (11), L. Lacambelz (12)  
(1) Hôpital R et G Laennec, C.M.R.R, Centre d’Investigation Clinique, Clinique Neurologique, Boulevard Jacques Monod, Nantes, France  
(2) Unité d’informatique et de statistiques médicales, DRC CHU de Nantes, Nantes, FRANCE  
(3) CMRR de Toulouse, Clinique neurologique, Hôpital Purpan, Place du Dr Baylac, Toulouse, FRANCE  
(4) CMRR de Bordeaux, Clinique neurologique, Hôpital Pellegrin, place A Raba Léon, Bordeaux, FRANCE  
(5) CMRR Ile de France, Service de Neurologie, Hôpital de la Salpêtrière, 47-48 boulevard de l’Hôpital, Paris, FRANCE  
(6) Unité de Neurologie, Hôpital Sainte-Marguerite, Marseille, FRANCE  
(7) CMRR de Limoges, Service de Neurologie, Hôpital Dupuytren, 2 Rue Martin Luther King, Limoges, FRANCE  
(8) CMRR de Saint Etienne, Clinique Neurologique, Hôpital Bellevue, 25 Boulevard Pasteur, Saint-Etienne, FRANCE  
(9) CMRR de Montpellier, MontpellierHôpital Gu de Chauliac 80 Avenue Augustin Fliche, Montpellier, FRANCE  
(10) INSERM U 679, Hôpital de la Salpêtrière, 47 boulevard de l’Hôpital, Paris, FRANCE  
(11) CHU Nantes DRCI, 5 avenue de l’île Gloriette, Nantes, FRANCE  
(12) Fédération des Maladies du Système Nerveux, APHP Hôpital de la Salpêtrière, UPMC Paris VI, Pharmacologie, INSERM U 678, Paris, FRANCE

5:15 - 5:30 p.m  
**O22 DEPRESSION IN ALZHEIMER’S DISEASE-2 (DIADS-2): A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF SERTRALINE FOR DEPRESSION OF ALZHEIMER’S DISEASE**  
P.B. Rosenberg, D. Weintraub, L.T. Drye, B.K. Martin, C. Frangakis, J.E. Mintzer, A.P. Porsteinsson, L.S. Schneider, P.V. Rabins, C.A. Munro, C.L. Meinert, C.G. Lyketsos, For the DIADS-2 Research Group  
Johns Hopkins University, Baltimore, MD, USA

*TBC
P1 DEVELOPMENT OF THE BRIEF DEMENTIA RISK INDEX: A SIMPLE TOOL TO IDENTIFY HIGH-RISK ELDERS FOR DEMENTIA PREVENTION TRIALS
(1) University of California, San Francisco and San Francisco va medical center, San Francisco, CA, USA
(2) Kaiser permanente division of research, Oakland, CA, USA
(3) University of Pittsburgh, Pittsburgh, PA, USA

P2 THE MENTAL ACTIVITY AND EXERCISE (MAX) TRIAL
D.E. Barnes, K. Yaffe, et al.
University of California, San Francisco and San Francisco va medical center, San Francisco, CA, USA

P3 ALZHEIMER DISEASE - MALNUTRITION AND NUTRITIONAL SUPPORT – COMPARATIVE AND INTERVENTION STUDY
(1) Psychiatric Clinic, dept.of Psychiatry, Masaryk University Hospital, Brno, CZECH REPUBLIC
(2) Institute of Biostatistics and Analyses
(3) Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, CZECH REPUBLIC
(4) Dept.of Clinical Nutrition, Masaryk University Hospital, Brno, CZECH REPUBLIC
(5) Pharmacology Dept., National University of Ireland, Galway, IRELAND
(6) Gerontometabolic Clinic, Charles University Hospital, Hradec Kralove, CZECH REPUBLIC

P4 CAN EVENT RELATED POTENTIAL (ERP) PREDICT THE PROGRESSION OF MCI? A PROSPECTIVE STUDY
K. Bennys (1), N. Reza (2), G. Rondouin (1), J. Touchon (1)
(1) Memory Research Resource Center for Alzheimer’s Disease, Department of Neurology, University Hospital of Montpellier, FRANCE
(2) University of Virginia School of Medicine, USA

P5 ART AND DEMENTIA : FIRST EUROPEAN STUDY OF THE ARTISTICS PRODUCTIONS AMONG DEGENERATIVE DEMENTIA
L. Bernard-Bourzeix, S. Durieux, A. Druet Cabanac, P. Couratier, T. Dantoine, J.P. Clément
CMRR Limousin, CHU-CHS, Limoges, FRANCE

P6 EPIGENETIC FACTORS IN AGING PROCESS: IMPLICATIONS IN GEROPROTECTORS DESIGN
N. Cucu (1), G. Anton (2), G.L. Radu (3), I. Turcu (4), L. Spiru (4)
(1) University of Bucharest, Epigenetics Lab, Bucharest, ROMANIA
(2) Stefan Nicolau Institute of Virology, Bucharest, ROMANIA
(3) National Institute of research and development in biological sciences, Bucharest, ROMANIA
(4) Ana Aslan International Academy of Aging, Bucharest, ROMANIA

P7 GENDER CORRELATES OF MILD COGNITIVE IMPAIRMENT (MCI) TO ALZHEIMER’S DISEASE (AD) CONVERSION
L. Spiru, I. Ioancio, C. Nuta, M. Blaciotti
Ana Aslan International Academy of Aging, Bucharest, ROMANIA

P8 NATURE AND NURTURE IN NORMAL BRAIN AGING AND IN ALZHEIMER’S DISEASE
L. Spiru, I. Turcu
Ana Aslan International Academy of Aging, Bucharest, ROMANIA
P9  HAVE WE SUFFICIENT INSIGHTS TO RECONSIDER PROCAINE AS A POTENT MOLECULE IN ALZHEIMER’S DISEASE?  
I. Turcu, L. Spiru  
Ana Aslan International Academy of Aging, Bucharest, ROMANIA

P10  SITE-SPECIFIC SCREENING AND ENROLLMENT RATES  
A. Gamst  
University of California, San Diego, La Jolla, CA, USA

P11  SHAPE-INVARIANT MODELING OF COGNITIVE DECLINE  
A. Gamst  
University of California, San Diego, La Jolla, CA, USA

P12  MEASUREMENT BURSTS IMPROVE PRECISION OF ESTIMATED RATE OF COGNITIVE DECLINE  
Albert Einstein College of Medicine, New York, USA

P13  ACCELERATED HIPPOCAMPAL ATROPHY IN SUBJECTS WITH MATERNAL HISTORY OF ALZHEIMER’S DISEASE  
University of California, Los Angeles, CA, USA

P14  EFFECTS OF MUSIC THERAPY ON ANXIETY AND DEPRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMIZED CONTROLLED TRIAL  
S. Guétin (1,2,4), F. Portet (1), M.C. Picot (3), C. Pommié (1,2), M. Messaoudi (1), L. Djabelkir (1), E. Lecourt (4), J. Touchon (1,2)  
(1) Service de Neurologie, Centre Mémoire de Ressources et de Recherches (CMRR); Inserm U888, CHRU Montpellier, Montpellier, FRANCE  
(2) Association de Musicothérapie Applications et Recherches Cliniques (AMARC), Paris, FRANCE  
(3) Département d’Information Médicale, CHRU Arnaud de Villeneuve, Montpellier, FRANCE  
(4) Laboratoire de Psychologie Clinique et Psychopathologie (LCPL) EA 4056; Université Paris-Descartes, Paris, FRANCE

P15  COGNITIVE EFFECTS OF PARKINSONIAN SIGNS IN OLDER PEOPLE IN A COMMUNITY-BASED STUDY  
M.H. Park (1), C. Han (2)  
(1) Departments of Neurology, Korea University College of Medicine, Ansan, REPUBLIC OF KOREA  
(2) Departments of Psychiatry, Korea University College of Medicine, Ansan, REPUBLIC OF KOREA

P16  EFFECT OF DONEPEZIL ON STRUCTURAL MRI AND CLINICAL MARKERS IN PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: a Randomized, placebo-controlled trial: THE HIPPOCAMPUS STUDY  
(1) INSERM-UPMC UMRS 610, Federation of Neurology, AP HP, Salpetrière Hospital, University Paris 6, Paris, FRANCE  
INSERM U610 unit,Federation of Neurology, ,Salpetrière hospital ,Paris, FRANCE  
(2) Cognitive Neuroscience and Brain Imaging Laboratory, CNRS UPR840, Salpetrière hospital, Paris, FRANCE  
(3) INSERM U610 unit, and CENIR, Neuro-imaging Unit, ,Salpetrière hospital , Paris, FRANCE  
(4) Eisai SAS, Paris, FRANCE
P17  EVP-6124, AN ALPHA-7 NICOTINIC AGONIST, PRODUCES PRO-COGNITIVE EFFECTS AND IS WELL TOLERATED IN ALZHEIMER’S DISEASE PATIENTS ON STABLE ACETYLCHOLINESTERASE INHIBITOR THERAPY

J. Apter (1), B. Safirstein (2), D. Hassman (3), S. Thein (4), P. Maruff (5), J. Harrison (5), M. Gawryl (6), D. Hilt (6)

(1) Global Medical Institutes, Princeton, NJ, USA
(2) MD Clinical, Hallandale Beach FL, USA
(3) Comprehensive Clinical Research, Berlin, NJ, USA
(4) Pacific Research Network, Inc. San Diego, CA, USA
(5) CogState Ltd, Melbourne, AUSTRALIA
(6) EnVivo Pharmaceuticals, Watertown, MA, USA

P18  THE DIFFERENTIAL DIAGNOSIS OF DEMENTIA – A STILL CHALLENGING FIELD

L. Spiru, I. Turcu, F. Halici
Ana Aslan International Academy of Aging, Bucharest, ROMANIA

P19  MORBI-MORTALITY PREDICTIVE WEIGHT LOSS THRESHOLD AT PATIENTS WITH ALZHEIMER’S DISEASE FOLLOWED IN AMBULATORY

O. Guérin (1), S. Et esse-Winckel (1), P. Robert (1), C. Cantet (2), B. Vellas (2)

(1) Department of gerontology and geriatrics, CMRR, CHU Nice, FRANCE
(2) Inserm U558, Department of internal medicine and geriatrics, CHU Toulouse, FRANCE

P20  ORAL MASITINIB IN PATIENTS SUFFERING FROM MILD-TO-MODERATE ALZHEIMER’S DISEASE

F. Piette (1), P. Cherubin (2), T.H. Bader (2), A. Moussy (2), O. Hermine (3)

(1) Hôpital Charles Foix, Ivry-sur-Seine, FRANCE
(2) AB Science, Paris, FRANCE
(3) Hôpital Necker, Paris, FRANCE

P21  THE NTB DEMONSTRATES HIGH TEST-RETETED AND INTERRATER RELIABILITY


(1) Harvard Medical School, Boston, MA, USA
(2) Imperial College, London, UK
(3) Elan Pharmaceuticals, Inc., South San Francisco, CA, USA
(4) Wyeth Pharmaceuticals, Collegeville, PA, USA.

P22  DESIGNING EARLY (PRE-DEMENTIA) ALZHEIMER’S DISEASE TRIALS : LINEAR MIXED MODELS VERSUS TIME TO CONVERSION

M. Donohue, A. Gamst, P. Aisen
University of California San Diego, San Diego, CA, USA

P23  ASSOCIATIONS BETWEEN TEMPORAL HORN VOLUMES DERIVED FROM MRI, CSF AB1-42 CONCENTRATIONS AND COGNITIVE DECLINE IN ADNI PARTICIPANTS

S.M. Nestor (1,2,4), M. Borrie (3,4), M. Smith (4), J.L. Wells (3,4), R. Bartha (1,2)

(1) Centre for functional and metabolic mapping, Robarts Research Institute, London, CANADA
(2) The departments of medical biophysics
(3) Medicine, University of Western Ontario, London, CANADA
(4) Division of aging, rehabilitation, and geriatric care, Lawson Health Research Institute, London, CANADA
P24  WHY EXERCISER TRAINING IS AN EFFICACIOS INTERVENTION FOR DEMENTIA?
P.C. Heyn
School of medicine, University of Colorado Denver, Denver, Colorado, USA

P25  PHYSICAL ACTIVITY IS ASSOCIATED WITH ENHANCED SEMANTIC MEMORY ACTIVATION IN OLDER APOE-ε4 CARRIERS
Cleveland Clinic, Medical College of Wisconsin, University of Wisconsin-Milwaukee, Marquette University, Rosalind Franklin University of Medicine and Science, and Wayne State University, USA

P26  MEASUREMENT OF EPISODIC MEMORY USING WORD-BASED TASKS IN DIFFERENT LANGUAGES : VALIDATION FROM MULTICENTER CLINICAL TRIALS
B.K. Saxby (1), R.E. Stacey (2), A.C. Embleton (2), N.A. Meinel (2), K.A. Wesnes (2)
(1) Cognitive Drug Research Ltd., Chicago, USA
(2) Cognitive Drug Research Ltd., Goring-on-Thames, USA

P27  MEASUREMENT OF APATHY AND NEUROPSYCHIATRIC SYMPTOMS IN CLINICAL TRIALS
P.H. Robert, E. Mullin, R. David, P. Malléa
Memory Center (CMRR) & Center for innovation in Health care (CIU-S), Nice, FRANCE

P28  MOLECULAR STATUS OF PLASMA FIBRONECTIN AS AN ADDITIONAL BIOMARKER FOR ASSESSMENT OF ALZHEIMER’S DEMENTIA RISK
J. Leszekb (2), A. Lemańska-Pereka (1), D. Krzyżanowska-Goląba (1), J. Radzikb (2), I. Katnik-Prastowskaa(1)
(1) Department of Chemistry and Immunochemistry, Wrocław University of Medicine, Bujwida 44a, 50-345 Wrocław, POLAND
(2) Department, and Clinic of Psychiatry, Wrocław University of Medicine, Pasteura 10, 51-348 Wrocław, POLAND

P29  COMPUTATIONAL APPROACHES FOR IDENTIFICATION OF NEW TARGETS AND PRE-CLINICAL VALIDATION
O.M. Mitrasinovic
Stanford University, CA, USA

P30  PROGNOSIS OF MILD COGNITIVE DEFICIT ABOUT THE EVOLUTION TO ALZHEIMER´S DISEASE
J. Villalobos, D. Sotomayor, G. Hernández, G. Orduz
Neurology Medical Center, University Of Sinu, Monteria, Cordoba, COLOMBIA

P31  PKR IS A TARGET FOR NEUROPROTECTION IN ALZHEIMER’S DISEASE
J. Hugon, C. Paquet, F. Mouton liger, A. Bose, F. Gray
Memory Center ( CMRR Paris Nord IdF) Hôpital Lariboisière Fernand Widal, Paris, Inserm UMR U839 Paris, FRANCE

P32  DIFFERENCES IN Β-AMYLOID POOL IN BLOOD DISCRIMINATE BETWEEN AMNESIC MILD COGNITIVE IMPAIRMENT PATIENTS (AMCI) AND HEALTHY CONTROLS (HC)
(1) Araclon Biotech, Zaragoza, SPAIN
(2) Fundació ACE, Barcelona, SPAIN
(3) Biometría Clínica, Barcelona, SPAIN
DENUTRITION IN THE ELDERLY SUFFERING FROM CANCER AND COGNITIVE IMPAIRMENT ADMITTED IN LIMOGES ONCOGERIATRIC UNIT
T. Dantoine (1,3), A. Challa (1), L. Sauvain (1,3), F. Lachal (1), A. Labrousse (1,3), M.A. Picat (1,3), C. Gayot (1,3), J. Martin (2,3), N. Tubiana-Mathieu (2,3)
(1) Pole de Gérontologie, CHU de Limoges, Limoges, FRANCE
(2) Service d’Oncologie Médicale, CHU de Limoges, Limoges, FRANCE
(3) Unité Piloté d’Oncogériatrie, CHU de Limoges, Limoges, FRANCE

EVALUATION OF THE B-AMYLOID POOL IN BLOOD BY ELISA SANDWICH IS MEANINGFUL AND RELIABLE
(1) Araclon Biotech, Zaragoza, SPAIN
(2) Fundación ACE, Barcelona, SPAIN
(3) Biometría Clínica, Barcelona, SPAIN

THE UNEXPECTED CAPACITY OF MELANIN TO DISSOCIATE THE WATER MOLECULE EXPLAINS THE COMMON HISTOLOGICAL FINDINGS BETWEEN ALZHEIMER’S DISEASE AND AGE-RELATED MACULAR DISEASE
A. Solís-Herrera, M. Del Carmen Arias Esparza, R.I. Solís-Arias, P.E. Solís-Arias, M.P. Solís-Arias
Human Photosynthesis Study Center, S.C., Life’s Sciences Division, MEXICO

DEVELOPMENT OF HOMOLOGOUS MARKERS TO MONITOR DISEASE PROGRESSION IN ANIMAL MODELS AND HUMANS
G.B. Frisoni (1), D. Bartres-Faz (2), C. Babiloni (3), F. Aujard (4), Y. Lamberty (5), R. Bordet (6), P. Payoux (7), J. Atack (8), E. Schenker (9), M.J. O’Neill (10), P. Verwaerde (11), G. Forloni (12), O. Deila-Pasqua (13), D. Wille (13), J. Georges (14), O. Blin (15), E.A. Irving (13)
(1) IRCCS Fatebenefratelli, Brescia, ITALY
(2) University of Barcelona, SPAIN
(3) University of Foggia, ITALY
(4) CNRS, FRANCE
(5) UCB Pharma
(6) University of Lille, FRANCE
(7) INSERM, FRANCE
(8) Janssen Pharmaceutica
(9) Institut de Recherche Servier
(10) Eli Lilly
(11) AlzProtect
(12) Mario Negri Institute, ITALY
(13) GlaxoSmithKline R&D, and the Pharma-Cog Consortium
(14) Alzheimer Europe
(15) University of Marseille, FRANCE

Posters will be displayed in La Tache room (where coffee breaks and lunches are being held) and listed by abstract number.

- Posters set-up: Thursday, October 29th from 8.00 to 9.30 a.m
- Posters take-out: Friday, October 30th from 4.00 to 5.30 p.m

(A technician will be available to help you with your poster display)
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Nevada School of Medicine and the Clinical Trials on Alzheimer’s Disease consortium. The University of Nevada School of Medicine is accredited by the ACCME to provide medical education to physicians.

The University of Nevada School of Medicine designates this educational activity for a maximum of 13.5 AMA PRA Category 1 Credits(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participant Sign-in and verification of Attendance

Participants are required to sign-in at the beginning of the activity and return a completed Activity Evaluation/Verification of Attendance form to the registration desk at the conclusion of the activity. Only those individuals who sign in and return an evaluation form will receive a certificate of attendance.

Replacement Certificates of Attendance

In the event a certificate of attendance is lost, please contact the Office of Continuing Medical Education for a replacement.

University of Nevada School of Medicine  (775) 784-1983
Office of Continuing Medical Education  (775) 784-4207 – fax
Reno, Nevada 89503 ocme@med.unr.edu

Disclosure Policy

As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, the University of Nevada School of Medicine requires that anyone in a position to control or influence the content of a continuing medical education activity disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented.

Nevada Geriatric Education Center, a joint program of the University of Nevada School of Medicine and the Sanford Center for Aging, provided support through funds from the Bureau of Health Professions (BHPr), Health Resources and Services Administration (HRSA), Department of Health and Human Services (DHHS) under grant number D31HP08800 and title of Geriatric Education Centers for a total award of $648,000.

The information or content and conclusions of this program are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by the BHPr, HRSA, DHHS or the U.S. Government.
Let’s meet next year in Toulouse, FRANCE

http://www.ctad.fr

CTAD Toulouse 2010

Clinical Trials on Alzheimer's Disease

November 3-5, 2010
Toulouse
Hôtel-Dieu Saint Jacques